Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis-Reference-Cited by-同舟云学术

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis

Published:2015-09-01 Issue:6 Volume:1 Page:836
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Héritier Sébastien¹,Jehanne Mathilde²,Leverger Guy¹,Emile Jean-François³,Alvarez Jean-Claude⁴,Haroche Julien⁵,Donadieu Jean¹

Affiliation:

1. Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique–Hôpitaux de Paris (APHP), Paris, France Trousseau Hospital, Paris, France

2. Department of Pediatric Hematology and Oncology, Felix Guyon Hospital, Saint-Denis Réunion, France

3. Pathology Department, Ambroise Paré Hospital, APHP, Boulogne, France

4. Department of Pharmacology and Toxicology, Raymond Poincaré Hospital, APHP, Garches, France

5. Department of Internal Medicine & French Reference Center for Rare Auto-immune & Systemic Diseases, Pitié-Salpêtrière Hospital, APHP, Paris, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium;Blood Neoplasia;2024-09

2. Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature;Cancer Reports;2024-08

3. Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib;Pediatric Blood & Cancer;2024-07-18

4. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G;The Oncologist;2024-06-14

5. One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas;Veterinary and Comparative Oncology;2024-06-12